Literature DB >> 29238165

Synthesis, characterization, and antimicrobial evaluation of novel 5-benzoyl-N-substituted amino- and 5-benzoyl-N-sulfonylamino-4-alkylsulfanyl-2-pyridones.

Galal Elgemeie1, Farag Altalbawy2,3, Mohammed Alfaidi3, Rania Azab2,4, Atef Hassan5.   

Abstract

The present research describes the synthesis of novel 5-benzoyl-N-substituted-amino- and 5-benzoyl-N-sulfonylamino-4-alkylsulfanyl-2-pyridones 5a-c and 6a-c via the reaction of n class="Chemical">2-benzoyl-3,3-bis(alkylthio)acrylonitriles 2a-c with N-cyanoacetohydrazide 3 and cyanoaceto-N-phenylsulfonylhydrazide 4, respectively. Also, the reactivity of the compounds 5a-c toward hydrazine hydrate to give product 1H-pyrazolo[4,3-c]pyridine derivative 7 was studied. In addition, the reactivity of the 2a-c toward 1-cyanoacetyl-4 arylidenesemicarbazides 8a-c afforded 3,5-dihydro[1,2,4]triazolo[1,5-a]pyridine-6-carbonitrile derivatives (12-14)a-c, which reacted with hydrazine hydrate to give 3H-pyrazolo[4,3-c][1,2,4]triazolo[1,5-a]pyridine-6-carbonitrile derivatives 15a-c. The structures of the new products were characterized based on 1H nuclear magnetic resonance, 13C nuclear magnetic resonance, infrared, mass-spectroscopy, and elemental analyses. The products were screened in vitro for their antibacterial and antifungal activity properties.

Entities:  

Keywords:  2-benzoyl-3,3-bis(alkylthio)acrylonitriles; 5-benzoyl-N-substituted-amino-4-alkylsulfanyl-2 pyridones; 5-benzoyl-N-sulfonylamino-4-alkylsulfanyl-2-pyridones; N-cyanoacetohydrazide; amino-2-pyridones; antimicrobial activity; cyanoaceto-N-phenylsulfonylhydrazide

Mesh:

Substances:

Year:  2017        PMID: 29238165      PMCID: PMC5713685          DOI: 10.2147/DDDT.S149615

Source DB:  PubMed          Journal:  Drug Des Devel Ther        ISSN: 1177-8881            Impact factor:   4.162


Introduction

Microorganisms that resist antimicrobial drugs are a complex problem affecting the health of n class="Species">people all over the world. More than 1 million people die from microbial infections every year, and the number of deaths is expected to increase as antimicrobial drug resistance increases.1 Innovation must be strengthened in research activities related to effective antimicrobial and antifungal drugs.2 N-substituted amino-2-pyridones are important heterocycles possessing a wide range of pharmaceutical applications.3 Many N-substituted amino-2-pyridones are known to possess antimicrobial and antifungal activities,4 antimalarials,5 and Alzheimer’s β-peptide aggregation inhibitors.6 In addition, sulfonyl heterocycles have a variety of pharmacological properties, such as apoptosis inhibition and ischemia treatment,7 metabolic liability,8 and glucokinase activation.9,10 We recently reported different innovative synthetic methods to prepare alkylsulfanyl, N-sulfonylamino and N-sulfonyl heterocycles, which found application and appear to constitute new classes of anticancer and antimicrobial agents.11–15 A series of one of our novel N-sulfonylpyrazoles were used by another group of research as an inhibitors of the enzyme cathepsin B.16 The studies demonstrated that N-sulfonylpyrazoles act as alternate substrates for cathepsin B, rather than as inhibitor metabolites. In another study, our N-sulfonylated pyrazoles were proven active as allosteric inhibitors of West Nile virus NS2B-NS3 proteinase.17 These promising results have motivated our research group to continue this work exploring novel molecular mechanisms of these synthetic compounds and their use as chemotherapeutic agents. In view of these findings and as a part of our program directed toward the preparation of potential antimetabolic agents,18–20 we recently reported different synthetic methods for preparation of azoloazines using cyanoketene dithioacetals.21–24 Derivatives of these ring systems are important as antimetabolic agents in biochemical reactions.25,26 In view of these reports and in continuation of our previous work in synthesis of bioactive heterocyclic compounds,27–34 the present research deals with a novel synthesis of 5-benzoyl-N-substituted amino- and 5-benzoyl-N-sulfonyl-amino-4-alkylsulfanyl-2-pyridones 5, 6 and 12–14 by the reaction of 2-benzoyl-3,3-bis(alkylthio) acrylonitriles 2a–c with substituted hydrazides.

Materials and methods

All melting points (MPs) were measured on an Electrothermal Gallenkamp apparatus (Weiss Tn class="Species">echnik, London, UK). Infrared (IR) spectra were recorded in potassium bromide disks on SP3300 (Pye Unicam, Cambridge, England) and 8101 PC (Shimadzu, Tokyo, Japan) IR spectrophotometers. 1H nuclear magnetic resonance (NMR) and 13C NMR spectra were recorded on a Varian Mercury VXR-300 spectrometer (300 MHz). Mass spectra were recorded on Shimadzu GCMS-Q1000-EX and GCMS 5988-A HP spectrometers, and ionizing voltage was 70 eV. Elemental analyses were carried out at the Microanalytical Center of Cairo University, Giza, Egypt. Biological evaluation of the products was carried out in the Microbiology Division of the Microanalytical Center of Cairo University.

Synthetic procedures

1,6-diamino-5-benzoyl-2-oxo-4-(alkylthio)-1,2-dihydropyridine-3-carbonitrile derivatives 5a–c and N-[6-amino-5-benzoyl-3-cyano-4-(alkylthio)-2-oxopyridin-1(2H)-yl]benzene-sulfonamide derivatives 6a–c

A mixture of 2-benzoyl-3,3-bis(alkylthio)acrylonitrile (2a–c) (0.01 mol), n class="Chemical">2-cyanoacetohydrazide (3) (0.99 g, 0.01 mol), and potassium hydroxide (0.67 g, 0.012 mol) in 1,4-dioxane (50 mL) was stirred at room temperature for 24 hours. The resultant product was acidified with hydrochloric acid. The precipitate formed was collected by filtration, washed with water, dried, and then crystallized from ethanol (EtOH)–dimethylformamide (DMF) to afford the corresponding compounds 5a–c. Repetition of the same procedure using the 2-benzoyl-3,3-bis(alkylthio)acrylonitrile 3a–c (0.01 mol) with 2-cyano-N′-(phenylsulfonyl)acetohydrazide (4) (2.39 g, 0.01 mol) yielded the respective products 6a–c.

1,6-diamino-5-benzoyl-4-(methylthio)-2-oxo-1, 2-dihydropyridine-3-carbonitrile (5a)

Yield (85%), MP 197°C (from EtOH-n class="Chemical">DMF); IR (KBr) νmax 3,426 (NH2), 2,923 (aliphatic CH), 2,214 (CN), 1,659 (C=O), 1,623 (C=C) cm−1; 1H NMR (DMSO-d6) – δ 2.89 (s, 3H, SCH3), 7.36–7.59 (m, 5H, ArH), 7.97 (s, 4H, 2NH2); 13C NMR (DMSO-d6) – δ 14.37 (SCH3), 84.86, 91.07, 115.13, 126.91, 129.39, 131.81, 140.06, 153.2, 155.8, 183.42, 188.66. MS m/z (%) 302 (M++2, 1.5), 301 (M++1, 1.1), 300 (M+, 10.5), 230 (30.71), 213 (20.16), 154 (21.47), 77 (100), 57 (55). Analysis calculated (Anal Calcd) for C14H12N4O2S (300.33): C, 55.99; H, 4.03; N, 18.65; S, 10.68. Found: C, 55.95; H, 4; N, 18.65; S, 10.66%.

1,6-diamino-5-benzoyl-4-(ethylthio)-2-oxo-1, 2-dihydropyridine-3-carbonitrile (5b)

Yield (80%), MP 281°C (from EtOH-n class="Chemical">DMF); IR (KBr) νmax 3,423 (NH2), 2,923, 2,857 (aliphatic CH), 2,210 (CN), 1,664 (C=O), 1,550 (C=C) cm−1; 1H NMR (DMSO-d6) – δ 1.21 (t, 3H, CH3), 2.89 (q, 2H, SCH2), 7.42–7.56 (m, 5H, ArH), 7.81 (s, 4H, 2 NH2). MS m/z (%): 316 (M++2, 2.81), 315 (M++1, 1.65), 314 (M+, 10.23), 291 (20.62), 275 (25.25), 211 (31.22), 106 (100), 75 (57.96), 56 (84.24). Anal Calcd for C15H14N4O2S (314.36): C, 57.31; H, 4.49; N, 17.82; S, 10.20. Found: C, 57.30; H, 4.43; N, 17.79; S, 10.14%.

1,6-diamino-5-benzoyl-2-oxo-4-(propylthio)-1, 2-dihydropyridine-3-carbonitrile (5c)

Yield (85%), MP >300°C (from EtOH-n class="Chemical">DMF); IR (KBr) νmax 3,427 (NH2), 2,925 (aliphatic CH), 2,208 (CN), 1,655 (C=O), 1,555 (C=C) cm−1; 1H NMR (DMSO-d6) – δ 0.85 (t, 3H, CH3), 1.5 (m, 2H, CH2), 2.78 (t, 2H, SCH2), 7.34–7.56 (m, 5H, ArH), 7.8 (s, 4H, 2NH2). MS m/z (%): 330 (M++2, 5.62), 329 (M++1, 3.21), 328 (M+, 8.62), 223 (38.55), 189 (40.23), 155 (22.42), 76 (100), 55 (85.87). Anal Calcd for C16H16N4O2S (328.39): C, 58.52; H, 4.91; N, 17.06; S, 9.76. Found: C, 58.48; H, 4.9; N, 17.05; S, 9.75%.

N-[6-amino-5-benzoyl-3-cyano-4-(mthylthio)-2-oxopyridin-1(2H)-yl]benzenesulfonamide (6a)

Yield (68%), MP 194°C (from EtOH-dioxane); IR (KBr) νmax – 3,421 (n class="Chemical">NH2), 2,935 (aliphatic CH), 2,219 (CN), 1,664 (C=O) cm−1; 1H NMR (DMSO-d6) – δ 2.78 (s, 3H, CH3), 7.35–7.68 (m, 10H, ArH), 8.14 (s, 2H, NH2), 9.22 (s, 1H, NH). MS m/z (%): 451 (M++1, 1.48), 454 (M+, 5.31), 440 (24.02), 409 (50.11), 330 (48.02), 175 (64.32), 77 (100), 55 (65.32). Anal Calcd for C20H16N4O4S2 (440.49): C, 54.53; H, 3.66; N, 12.72; S, 14.56. Found: C, 54.51; H, 3.63; N, 12.71; S, 14.53%.

N-[6-amino-5-benzoyl-3-cyano-4-(ethylthio)-2-oxopyridin-1(2H)-yl]benzenesulfonamide (6b)

Yield (82%), MP 225°C (from EtOH-dioxane); IR (KBr) νmax – 3,430 (n class="Chemical">NH2), 2,925 (aliphatic CH), 2,215 (CN), 1,660 (C=O), 1,549 (C=C) cm−1; 1H NMR (DMSO-d6) – δ 1.38 (t, 3H, CH3), 2.99 (q, 2H, SCH2), 7.41–7.87 (m, 10H, ArH), 8.17 (s, 2H, NH2), 9.1 (s, 1H, NH). MS m/z (%): 455 (M++1, 1.05), 454 (M+, 2.11), 198 (54.22), 182 (45.11), 151 (60.52), 79 (100), 57 (65.32). Anal Calcd for C21H18N4O4S2 (454.52): C, 55.49; H, 3.99; N, 12.33; S, 14.11. Found: C, 55.42; H, 3.9; N, 12.31; S, 14.07%.

N-[6-amino-5-benzoyl-3-cyano-4-(propylthio)-2-oxopyridin-1(2H)-yl]benzenesulfonamide (6c)

Yield (54%), MP 212°C (from EtOH-dioxane); IR (KBr) νmax – 3,417 (n class="Chemical">NH2), 2,922 (aliphatic CH), 2,211 (CN), 1,668 (C=O), 1,558 (C=C) cm−1; 1H NMR (DMSO-d6) – δ 0.96 (t, 3H, CH3), 1.49 (m, 2H, CH2), 2.86 (t, 2H, SCH2), 7.39–7.76 (m, 10H, ArH), 8.1 (s, 2H, NH2), 9.31 (s, 1H, NH). MS m/z (%): 469 (M++1, 0.65), 468 (M+, 1.81), 414 (24.02), 330 (42.11), 153 (67.5), 77 (100), 55 (65.54). Anal Calcd for C20H20N4O4S2 (468.55): C, 56.39; H, 4.3; N, 11.96; S, 13.69. Found: C, 56.32; H, 4.28; N, 11.91; S, 13.58%.

4,5-diamino-6-oxo-3-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridine-7-carbonitrile (7)

To a solution of compound 1,6-diamino-5-benzoyl-4-(alkylthio)-2-oxo-1,2-dihydropyridine-3-carbonitrile (5a–c) (0.005 mol) in absolute n class="Chemical">EtOH, an equivalent amount of hydrazine hydrate was added, and then the reaction mixture was heated under reflux for 7 hours, cooled, and poured onto cold water. The solid that precipitated was filtered off, dried, and finally crystallized from mEtOH-water to give 7. Yield (95%), MP 138°C (from water-mEtOH); IR (KBr) νmax – 3,433, 3,141 (NH and NH2), 3,094 (ArH), 2,924 (aliphatic CH), 2,222 (CN), 1,629 (C=O), 1,562 (C=C) cm−1; 1H NMR (DMSO-d6) – δ 7.49–7.8 (m, 5H, ArH), 8.31 (s, 4H, 2NH2), 14.31 (s, 1H, NH). MS m/z (%): 268 (M++2, 0.01), 267 (M++1, 0.02), 266 (M+, 0.02), 247 (1.53), 201 (2.17), 189 (3.29), 143 (2.84), 135 (2.39), 127 (3.23), 117 (12.87), 113 (17.49), 101 (14.82), 87 (21), 59 (100). Anal Calcd for C13H10N6O (266.25): C, 58.64; H, 3.79; N, 31.56%. Found: C, 58.61; H, 3.72; N, 31.5%.

8-benzoyl-2-(aryl)-7-(alkylthio)-5-oxo-3,5-dihydro[1,2,4]triazolo[1,5-a]pyridine-6-carbonitrile (12–14)a–c

A mixture of 2-benzoyl-3,3-bis(methylthio)acrylonitrile (2a) (0.01 mol), n class="Chemical">N′-[(aryl)-methylene]-2-cyanoacetohydrazide (8a–c) (0.01 mol) and potassium hydroxide (0.67 g, 0.012 mol) in 1,4-dioxane (50 mL) was stirred at room temperature for 24 hours. The resultant product was acidified with hydro-chloric acid while stirring. The solid that precipitated was filtered off, dried, and crystallized from EtOH-dioxane to give the respective compounds 12a–c. The same procedure was repeated using each of 2-benzoyl-3,3-bis(ethylthio)acrylonitrile (2b) and 2-benzoyl-3,3-bis(propylthio)acrylonitrile (2c). N′-[(aryl)-methylene]-2-cyanoaceto-hydrazide (8a–c) yielded the 13a–c and 14a–c.

8-benzoyl-2-(4-methoxyphenyl)-7-(methylthio)-5-oxo-3,5-dihydro[1,2,4]triazolo[1,5-a]pyridine-6-carbonitrile (12a)

Yield (90%), MP >300°C (from dioxane); IR (KBr) νmax – 3,433 (n class="Chemical">NH), 3,059 (aromatic CH), 2,923 (aliphatic CH), 2,211 (CN), 1,656 (C=O), 1,610 (C=C) cm−1; 1H NMR (DMSO-d6) – δ 3.65 (s, 3H, SCH3), 3.82 (s, 3H, OCH3), 6.85–8.15 (m, 9H, ArH), 12.05 (s, 1H, NH); 13C NMR (DMSO-d6) – δ 19.23 (SCH3), 55.63 (OCH3), 72.29, 81.5, 114.97, 117.05, 126.51, 128.37, 130.03, 130.83, 133.63, 140.57, 151.55, 152.22, 157.69, 161.53, 178.75, 186.65. MS m/z (%): 419 (M++3, 1.37), 418 (M++2, 1.36), 417 (M++1, 1.57), 416 (M+, 2.97), 415 (M+−1, 11.56), 414 (M+−2, 9.44), 133 (18.08), 105 (64.83), 77 (88.29), 63 (100), 57 (15.52). Anal Calcd for C22H16N4O3S (416.45): C, 63.45; H, 3.87; N, 13.45; S, 7.7. Found: C, 63.42; H, 3.85; N, 13.42; S, 7.68%.

8-benzoyl-7-(methylthio)-5-oxo-2-phenyl-3,5-dihydro[1,2,4]triazolo[1,5-a]pyridine-6-carbonitrile (12b)

Yield (88%), MP 220°C (from EtOH-dioxane); IR (KBr) νmax – 3,430 (n class="Chemical">NH), 3,059 (aromatic CH), 2,923 (aliphatic CH), 2,212 (CN), 1,658 (C=O), 1,549 (C=C) cm−1; 1H NMR (DMSO-d6) – δ 3.55 (s, 3H, SCH3), 6.95–8.1 (m, 10H, ArH), 12 (s, 1H, NH); 13C NMR (DMSO-d6) – δ 16.9 (SCH3), 87.5, 92.5, 114.5, 117.55, 127.7, 128.04, 129.73, 130.16, 131.65, 134.27, 137.55, 147.5, 151.9, 161.96, 178.55, 185.5. MS m/z (%): 387 (M++1, 12.52), 386 (M+, 12.7), 385 (M+−1, 5.47), 206 (10.95), 131 (37.72), 105 (86.18), 77 (100), 63 (87), 57 (25.64). Anal Calcd for C21H14N4O2S (386.42): C, 65.27; H, 3.65; N, 14.5; S, 8.3. Found: C, 65.22; H, 3.55; N, 14.45; S, 8.25%.

8-benzoyl-2-(4-chlorophenyl)-7-(methylthio)-5-oxo-3,5-dihydro[1,2,4]triazolo[1,5-a]pyridine-6-carbonitrile (12c)

Yield (85%), MP >300°C (from EtOH-n class="Chemical">DMF); IR (KBr) νmax – 3,429 (NH), 3,065 (aromatic CH), 2,922 (aliphatic CH), 2,205 (CN), 1,648 (C=O), 1,605 (C=C) cm−1; 1H NMR (DMSO-d6) – δ 3.5 (s, 3H, SCH3), 6.15–8.15 (m, 9H, ArH), 12.1 (s, 1H, NH); 13CNMR (DMSO-d6) – δ 19.22 (SCH3), 83.51, 111.36, 119.92, 128.18, 128.9, 129.13, 130.8, 133.67, 134.75, 138.64, 141.06, 152.37, 157.35, 157.53, 161.28, 192.72. MS m/z (%): 420 (M+, 1.59), 419 (M+−1, 1.72), 136 (100), 111 (11.15), 105 (55.52), 102 (46.9), 105 (86.18), 77 (48.59), 63 (75.48), 55 (13.07), 51 (28.75). Anal Calcd for C21H13ClN4O2S (420.87): C, 59.93; H, 3.11; N, 13.31; S, 7.62. Found: C, 59.9; H, 3.1; N, 13.3; S, 7.6%.

8-benzoyl-7-(ethylthio)-2-(4-methoxyphenyl)-5-oxo-3,5-dihydro[1,2,4]triazolo[1,5-a]pyridine-6-carbonitrile (13a)

Yield (85%), MP 235°C (from EtOH); IR (KBr) νmax – 3,440 (n class="Chemical">NH), 3,035 (aromatic CH), 2,931 (aliphatic CH), 2,212 (CN), 1,658 (C=O), 1,606 (C=C) cm−1; 1H NMR (DMSO-d6) – δ 1.32 (t, 3H, CH3), 3.76 (q, 2H, SCH2), 3.88 (s, 3H, OCH3), 6.97–8.21 (m, 9H, ArH), 11.47 (s, 1H, NH); MS m/z (%): 432 (M++2, 0.01), 431 (M++1, 0.01), 430 (M+, 0.01), 405 (0.2), 379 (0.19), 329 (0.14), 305 (0.74), 271 (0.51), 259 (1.73), 201 (2.54), 189 (3.21), 143 (4.47), 117 (18.29), 101 (17.1), 59 (100). Anal Calcd for C23H18N4O3S (430.48): C, 64.17; H, 4.21; N, 13.01; S, 7.45. Found: C, 64.1; H, 4.2; N, 13; S, 7.4%.

8-benzoyl-7-(ethylthio)-5-oxo-2-phenyl-3,5-dihydro[1,2,4]triazolo[1,5-a]pyridine-6-carbonitrile (13b)

Yield (85%), MP 172°C (from EtOH); IR (KBr) νmax – 3,430 (n class="Chemical">NH), 3,045 (aromatic CH), 2,924 (aliphatic CH), 2,207 (CN), 1,656 (C=O), 1,595 (C=C) cm−1; 1H NMR (DMSO-d6) – δ 1.23 (t, 3H, CH3), 3.31 (q, 2H, SCH2), 7.31–7.87 (m, 10H, ArH), 11.21 (s, 1H, NH). MS m/z (%): 402 (M++2, 0.01) 401 (M++1, 0.01), 400 (M+, 0.01), 379 (0.12), 317 (0.3), 289 (0.44), 260 (0.36), 201 (2.29), 189 n(3.11), 131 (5.01), 117 (18.13), 87 (19.74), 59 (100). Anal Calcd for C22H16N4O2S (400.45): C, 65.98; H, 4.03; N, 13.99; S, 8.01. Found: C, 65.91; H, 4; N, 13.92; S, 8%.

8-benzoyl-2-(4-chlorophenyl)-7-(ethylthio)-5-oxo-3,5-dihydro[1,2,4]triazolo[1,5-a]pyridine-6-carbonitrile (13c)

Yield (85%), MP 161°C (from EtOH); IR (KBr) νmax – 3,439 (n class="Chemical">NH), 3,055 (aromatic CH), 2,924 (aliphatic CH), 2,219 (CN), 1,667 (C=O), 1,606 (C=C) cm−1; 1H NMR (DMSO-d6) – δ 1.23 (t, 3H, CH3), 3.48 (q, 2H, SCH2), 7.35–7.63 (m, 9H, ArH), 11.21 (s, 1H, NH). MS m/z (%): 435 (M++1, 0.09), 434 (M+, 0.12), 307 (0.63), 280 (0.66), 248 (0.67), 201 (1.79), 143 (2.44), 131 (4.69), 113 (18.27), 87 (18.5), 59 (100). Anal Calcd for C22H15ClN4O2S (434.89): C, 60.76; H, 3.48; Cl, 8.15; N, 12.88; S, 7.37. Found: C, 60.7; H, 3.4; Cl, 8.1; N, 12.81; S, 7.3%.

8-benzoyl-2-(4-metoxyphenyl)-7-(propylthio)-5-oxo-3,5-dihydro[1,2,4]triazolo[1,5-a]pyridine-6-carbonitrile (14a)

Yield (85%), MP 240°C (from EtOH-dioxane); IR (KBr) νmax – 3,430 (n class="Chemical">NH), 3,061 (aromatic CH), 2,924 (aliphatic CH), 2,212 (CN), 1,626 (C=O) cm−1; 1H NMR (DMSO-d6) – δ 0.93 (t, 3H, CH3), 1.64 (m, 2H, CH2), 2.47 (t, 2H, SCH2), 3.34 (s, 3H, OCH3), 6.96–7.76 (m, 9H, ArH), 11.68 (s, 1H, NH). MS m/z (%): 446 (M++2, 0.05), 445 (M++1, 0.08), 444 (M+, 1.1), 369 (3.2), 292 (12.56), 184 (23.21), 177 (41.25), 105 (35.34), 77 (42.75), 57 (100). Anal Calcd for C24H20N4O3S (444.5): C, 64.85; H, 4.54; N, 12.6; S, 7.21. Found: C, 64.81; H, 4.52; N, 12.58; S, 7.2%.

8-benzoyl-5-oxo-2-phenyl-7-(propylthio)-3,5-dihydro[1,2,4]triazolo[1,5-a]pyridine-6-carbonitrile (14b)

Yield (85%), MP >300°C (from EtOH-n class="Chemical">DMF); IR (KBr) νmax – 3,438 (NH), 2,925 (aliphatic CH), 2,213 (CN), 1,658 (C=O), 1,612 (C=C) cm−1; 1H NMR (DMSO-d6) – δ 0.96 (t, 3H, CH3), 1.46 (m, 2H, CH2), 2.28 (t, 2H, SCH2), 7.4–8.25 (m, 10H, ArH), 11.21 (s, 1H, NH). MS m/z (%): 416 (M++2, 1.12), 415 (M++1, 1.26), 414 (M+, 2.13), 338 (23.21), 261 (53.36), 215 (25.13), 105 (56.26), 77 (38.49), 57 (100). Anal Calcd for C23H18N4O2S (414.48): C, 66.65; H, 4.38; N, 13.52; S, 7.74. Found: C, 66.6; H, 4.31; N, 13.5; S, 7.7%.

8-benzoyl-2-(4-chlorophenyl)-5-oxo-7-(propylthio)-3,5-dihydro[1,2,4]triazolo[1,5-a]pyridine-6-carbonitrile (14c)

Yield (85%), MP 280°C (from EtOH-dioxane); IR (KBr) νmax – 3,428 (n class="Chemical">NH), 3,154 (aromatic CH), 2,923 (aliphatic CH), 2,214 (CN), 1,670 (C=O), 1,617 (C=C) cm−1; 1H NMR (DMSO-d6) – δ 1.03 (t, 3H, CH3), 1.4 (m, 2H, CH2), 2.86 (t, 2H, SCH2), 7.13–8.23 (m, 9H, ArH), 11.36 (s, 1H, NH). Anal Calcd for C23H17ClN4O2S (448.92): C, 61.53; H, 3.82; Cl, 7.9; N, 12.48; S, 7.14. Found: C, 61.5; H, 3.8; Cl, 7.89; N, 12.4; S, 7.1%.

2-(aryl)-5-oxo-9-phenyl-5,7-dihydro-3H-pyrazolo[4,3-c][1,2,4]triazolo[1,5-a]pyridine-6-carbonitriles 15a–c

To a solution of each compound (12–14)a–c (0.005 mol) in dioxane, equivalent amounts of n class="Chemical">hydrazine hydrate were added, and then the reaction mixture was heated under reflux for 12 hours, cooled, and then poured onto cold water. The solid that precipitated was filtered off, dried, and finally crystallized from EtOH-dioxane to give the 15a–c at good yield.

2-(4-methoxyphenyl)-5-oxo-9-phenyl-5,7-dihydro-3H-pyrazolo[4,3-c][1,2,4]triazolo[1,5-a]-pyridine-6-carbonitrile (15a)

Yield (65%), MP 193°C (from EtOH-dioxane); IR (KBr) νmax – 3,445 (n class="Chemical">NH), 3,112 (aromatic CH), 2,945 (aliphatic CH), 2,218 (CN), 1,674 (C=O), 1,613 (C=C) cm−1; 1H NMR (DMSO-d6) – δ 3.54 (s, 3H, OCH3), 6.96–8.01 (m, 9H, ArH), 11.31 (s, 1H, NH); 12.15 (s, 1H, NH). MS m/z (%): 384 (M++2, 1.01), 383 (M++1, 1.06), 382 (M+, 2.18), 368 (25.41), 294 (55.32), 267 (25.11), 105 (100), 77 (38.99), 57 (95.21). Anal Calcd for C21H14N6O2 (382.37): C, 65.96; H, 3.69; N, 21.98. Found: C, 65.91; H, 3.6; N, 12.4%.

5-oxo-2,9-diphenyl-5,7-dihydro-3H-pyrazolo[4,3-c] [1,2,4]triazolo[1,5-a]pyridine-6-carbonitrile (15b)

Yield (73%), MP 202°C (from EtOH-dioxane); IR (KBr) νmax – 3,435 (n class="Chemical">NH), 3,120 (aromatic CH), 2,222 (CN), 1,670 (C=O), 1,618 (C=C) cm−1; 1H NMR (DMSO-d6) – δ 7.02–7.98 (m, 10H, ArH), 11.22 (s, 1H, NH); 12.11 (s, 1H, NH). MS m/z (%): 354 (M++2, 0.06), 353 (M++1, 1), 352 (M+, 1.1), 326 (28.11), 274 (57.3), 206 (32.1), 105 (100), 77 (53.94), 57 (65.11). Anal Calcd for C20H12N6O (352.34): C, 68.17; H, 3.43; N, 23.85. Found: C, 68.11; H, 3.39; N, 23.68%.

2-(4-chlorophenyl)-5-oxo-9-phenyl-5,7-dihydro-3H-pyrazolo[4,3-c][1,2,4]triazolo[1,5-a]-pyridine-6-carbonitrile (15c)

Yield (73%), MP 231°C (from EtOH-dioxane); IR (KBr) νmax – 3,422 (n class="Chemical">NH), 3,110 (aromatic CH), 2,215 (CN), 1,665 (C=O), 1,610 (C=C) cm−1; 1H NMR (DMSO-d6) – δ 6.892–7.88 (m, 9H, ArH), 11.52 (s, 1H, NH); 12.31 (s, 1H, NH). MS m/z (%): 388 (M++2, 1.23), 387 (M++1, 1.42), 386 (M+, 3.14), 352 (35.32), 275 (47.12), 200 (52.14), 105 (100), 77 (51.66), 57 (45.18). Anal Calcd for C20H11ClN6O (386.79): C, 62.1; H, 2.87; Cl, 9.17; N, 21.73. Found: C, 61.97; H, 2.82; Cl, 9; N, 21.65%.

Antimicrobial evaluation

The yeast of n class="Species">Candida albicans and bacteria of Staphylococcus aureus and Escherichia coli were used in this study to evaluate the antifungal and antibacterial potential of the synthesized compounds. The selected isolates were recovered from diseased cases of humans and animals at the Laboratory of Microbiology, Health Research Institute, Cairo, Egypt.

Control antibacterial and antifungal

The control antifungal (fluconazole 20 μg) and antibacterial (n class="Chemical">levofloxacin 3.25 μg) were purchased from Sigma-Aldrich (St Louis, MO, USA) and used as comparable controls.

Evaluation of antimicrobial potential of synthesized compounds against C. albicans, S. aureus, and E. coli using well diffusion test

Spore suspension (1 mL) was added to adjust the inoculum of S. aureus and n class="Species">E. coli to 2.5×103 cells/mL and C. albicans to 5×104 cells/mL were incorporated with Sabouraud dextrose agar (SDA) medium plates (for yeast) or nutrient agar medium (for bacteria). Wells of 5 mm Φ were made on the medium surface of agar plates, and 100 μL of gradual concentrations (0, 1, 2, 3, 4 and 5 mg/mL) of the synthe-sized compounds was added to the wells. Then, plates were incubated at 35°C–37°C for 24–72 hours. After incubation, the plates were tested for growth-inhibitory concentration zones around wells in the SDA medium plates (for yeast) or nutrient agar medium plates (for bacteria). Similar methods were used for control antifungal and antibacterial.35–37

Evaluation of antimicrobial potential of synthesized compounds against C. albicans, S. aureus, and E. coli using broth-dilution antifungal susceptibility testing of filamentous fungi

The minimum inhibitory concentration (MIC) of synthesized compounds for the tested isolates was determined by a broth-microdilution method based on the National Committee for Clinin class="Species">cal Laboratory Standards. In sterile 12×75 mm plastic test tubes, 900 μL of RPMI 1640 broth medium or SD broth medium (for fungi) or nutrient broth (for bacteria) was inoculated separately, then 100 μL spore suspension added to adjust the inocula of S. aureus, E. coli (2.5×103 cells/mL), and Candida albicans to 5×104 cells/mL, and 100 μL of tested synthesized compound concentrations (1, 2, 3, 4, 5 mg/mL) for bacteria and fungi were added. The traditional antifungal agent fluconazole (20 μg) and antibacterial agent levofloxacin (3.25 μg) were included in separate assays as positive controls.38 The experiment was repeated twice. The MIC for fungi and bacteria was defined as the lowest synthesized compound concentration that showed no visible fungal or bacterial growth after incubation. After incubation, 5 μL of tested broth was inoculated on the sterile nutrient agar plates for bacteria and n class="Chemical">SDA plate for fungi and incubated at 37°C for 24 hours to 2 weeks. The MIC was determined as the lowest concentration of synthesized compounds inhibiting the visual growth of the test cultures on the agar plate. The turbidity of the growth in tubes was observed every 24 hours. Growth was assayed by measurement of optical density and transmittance of the contents of each tube at 405 nm using spectrophotometry.

Scanning electron microscopy of treated microbial cells

Morphological changes in n class="Species">C. albicans, S. aureus, and E. coli treated by the synthesized compound were observed with scanning electron microscopy (SEM). All tube contents were centrifuged and the sediments of each dehydrated separately through a graded series of EtOH (30%, 50%, 60%, 70%, 80%, 90%, 95%, and 100%), each level was applied twice for 15 minutes each time, and then EtOH:isoamyl acetate (3:1, 1:1, 1:3) and 100% isoamyl acetate were applied twice for 30 minutes. Solutions in wells were dried with a critical-point drier using liquid CO2 and coated with gold for 5 minutes. Coated samples were observed under SEM (JSM-5600LV) with accelerating voltage of 10 kVj.39

Results

Chemistry

It was found that 2-benzoyl-3,3-bis(alkylthio)acrylonitriles 2a–c prepared by the reaction of benzoyl acetonitrile 1, n class="Species">carbon disulfide, and alkyl iodide in the presence of sodium hydride reacted with cyanoaceto-N-phenylsulfonylhydrazide 4 at room temperature for 24 hours in the presence of KOH-dioxane to give the corresponding 5-benzoyl-N-[4-(alkylthio)-2-oxopyridin-1(2H)-yl]benzenesulfonamide 6a–c. Structures of 6a–c were established on the basis of spectroscopic data and elemental analysis (13C NMR, 1H NMR, IR, MS; Scheme 1). Compound 6 can also be prepared by reaction of the corresponding 1,6-diamino-5-benzoyl-2-oxo-4-(alkylthio)-1,2-dihydropyridine-3-carbonitriles 5a–c with benzene sulfonyl chloride in KOH-dioxane. When 2-benzoyl-3,3-bis(alkylthio)acrylonitriles 2a–c was treated with cyanoacetohydrazide 3 at room temperature for 24 hours in the presence of KOH-dioxane, 5a–c was obtained at excel-lent yield. Compound 5 reacted with hydrazine in refluxing EtOH to give the pyrazolopyridine 7. The structure of compound 7 was established on the basis of elemental analysis and spectral data, as outlined in Scheme 1.
Scheme 1

Synthesis of 1,6-diamino-5-benzoyl-4-(alkylthio)-2-oxo-1,2-dihydropyridine-3-carbonitrile derivatives 5a–c and N-[6-amino-5-benzoyl-3-cyano-4-(alkylthio)-2-oxopyridin-1(2H)-yl]benzene-sulfonamide derivatives 6a–c and 4,5-diamino-6-oxo-3-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridine-7-carbonitrile (7).

In order to explore the reactivity of cyanoketene dithioacetals 2 with other classes of substituted n class="Chemical">cyanoacetohydrazide, we investigated the reaction of 2a–c with N′-[(aryl)-methylene]-2-cyanoacetohydrazides 8a–c. As such, we treated 8a–c with one equivalent of compound 2a–c in KOH-dioxane at room temperature for 24 hours and obtained the corresponding 7-(alkylthio)-3,5-dihydro[1,2,4] triazolo[1,5-a]pyridines 12–14 at good yield. The structure of 12–14 was established on the basis of its IR, MS, 1H NMR, spectroscopic, and elemental analysis. The formation of 12–14 from 2 and 8 was assumed to proceed via inter-mediate Michael adducts 9–11, which cyclized to yield the novel triazolopyridine derivatives 12–14. Compounds 12–14 reacted with hydrazine in refluxing dioxane to give the corresponding pyrazolo[4,3-c][1,2,4]triazolo[1,5-a]pyridines 15a–c. The structure of compound 15 was established on the basis of elemental analysis and spectral data, as outlined in Scheme 2.
Scheme 2

Synthesis of 8-benzoyl-2-(aryl)-7-(alkylthio)-5-oxo-3,5-dihydro[1,2,4]triazole-[1,5-a]pyridine-6-carbonitrile (12–14)a–c and 2-(aryl)-5-oxo-9-phenyl-5,7-dihydro-3H-pyrazolo[4,3-c][1,2,4]triazolo[1,5-a]pyridine-6-carbonitrile 15a–c.

In the present work, the antifungal and antibacterial potentials of synthesized compounds were evaluated against C. albicans, n class="Species">S. aureus, and E. coli using well diffusion tests. Inhibition-zone diameters for C. albicans were larger than for bacteria of S. aureus and E. coli strains (Tables 1 and 2). The MIC of synthesized compounds 6a–c and 15a–c was 4 mg/mL. Compound 6c had more antibacterial potential against S. aureus and E. coli, and showed zones of growth inhibition of 12 and 18 mm, respectively, at a concentration of 5 mg/mL. Other synthesized compounds – 5a–c, 7, 15a–b, and 12a–c – showed no antimicrobial potential up to a concentration of 5 mg/mL. On the other hand, the antifungal potential of the chemicals used showed more pronounced effects at comparatively lower concentrations, where the MIC against C. albicans was 1 mg/mL. The MIC of antifungal potential of synthesized compounds 6a–c and 15a–c was 1 mg/mL, while for chemicals of 15b the MIC was 4 mg/mL. The zone of fungal inhibition of chemical number 15c was 20 mm at a concentration of 1 mg/mL, and reached 35 mm at a concentration of 5 mg/mL. Other tested compounds showed no antimicrobial potential till concentrations had reached 5 mg/mL.
Table 1

Antibacterial and antifungal activity of synthesized compounds 5a–c, 6a–c, 7, 12a–c, and 15a–c against Staphylococcus aureus (SA), Escherichia coli (EC), and Candida albicans (CA) isolates using well diffusion test

CompoundZone-area inhibition (mm) of synthesized compounds at gradual concentration (mg/mL)*
1
2
3
4
5
SAECCASAECCASAECCASAECCASAECCA
5a000000000000000
5b000000000000000
5c000000000000000
6a00100012001410025121130
6b001000150020111020121222
6c0010001501018101522121825
7000000000000000
12a000000000000000
12b000000000000000
12c000000000000000
15a0015002000220102401325
15b000000000101110121513
15c002000200025101230101535

Notes:

For the control antifungal (fluconazole 20 μg), the zone of inhibition was 15 mm, and for the control antibacterial (levofloxacin 3.25 μg), the zone of inhibition was 18 mm. ATCC designations for EC, SA, and CA 11775, 12600, and 26555, respectively.

Table 2

Transmittance and turbidity of treated Staphylococcus aureus and Escherichia coli with the synthesized compounds 5a–c, 6a–c, 7, 12a–c, and 15a–c

CompoundTransmittance of treated microbial cells*
S. aureus
E. coli
4 mg/mL
5 mg/mL
4 mg/mL
5 mg/mL
T% (clearance)#Degree of turbidityT% (clearance)#Degree of turbidityT% (clearance)#Degree of turbidityT% (clearance)#Degree of turbidity
Untreated2++++2++++2++++2++++
5a95+975++++95+
5b95+9793++100
5c95+97100100
6a0++++0++++0++++0++++
6b0++++0++++0++++0++++
6c0++++0++++0++++0++++
70++++0++++0++++0++++
12a0++++0++++0++++0++++
12b0++++0++++0++++0++++
12c0++++0++++0++++0++++
15a0++++0++++94++97+
15b95+96+96+100
15c95+95+100100

Notes:

Control antibacterial levofloxacin 3.25 μg;

transmittance of treated spores at λ=405 nm.

In the present study, the scanning of treated fungal and bacterial cells by SEM analysis showed interactions between synthesized compounds and the membrane structure of bacterial or fungal cells through signifin class="Species">cant changes to their membranes, recognized by the formation of “pits” on their surfaces, and finally resulted in the formation of pores and cell death and hence increasing the antimicrobial function of these compounds (Figures 1–3).
Figure 1

(A) Scanning electron microscopy of normal Candida albicans cells and (B) treated C. albicans cells.

Figure 2

(A) Scanning electron microscopy of normal Staphylococcus aureus cells and (B) treated S. aureus cells.

Figure 3

(A) Scanning electron microscopy of normal Escherichia coli cells and (B) treated E. coli cells.

Conclusion

In summary, we achieved a region-specific synthesis of novel n class="Chemical">5-benzoyl-N-substituted amino- and 5-benzoyl-N-sulfonylamino-4-alkylsulfanyl-2-pyridones and their corresponding pyrazolopyridines and pyrazolotriazolopyridones by the reaction of 2-benzoyl-3,3-bis(alkylthio)acrylonitriles 2a–c with cyanohydrazide 3 and its derivatives 4 and 8. The antibacterial potential of the synthesized compounds was evaluated in order to assess their antimicrobial potential.
  22 in total

1.  Nucleic acid components and their analogs: Design and synthesis of novel cytosine thioglycoside analogs.

Authors:  Galal H Elgemeie; Ali M Salah; Nermeen S Abbas; Hoda A Hussein; Reham A Mohamed
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2017-01-03       Impact factor: 1.381

2.  Pyrimidine non-nucleoside analogs: A direct synthesis of a novel class of N-substituted amino and N-sulfonamide derivatives of pyrimidines.

Authors:  Galal H Elgemeie; Ali M Salah; Nermeen S Abbas; Hoda A Hussein; Reham A Mohamed
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2017-01-19       Impact factor: 1.381

3.  Synthesis of pyrazole encompassing 2-pyridone derivatives as antibacterial agents.

Authors:  Nisheeth C Desai; Kiran M Rajpara; Vivek V Joshi
Journal:  Bioorg Med Chem Lett       Date:  2013-02-26       Impact factor: 2.823

Review 4.  The 2-pyridone antibacterial agents: bacterial topoisomerase inhibitors.

Authors:  Q Li; L A Mitscher; L L Shen
Journal:  Med Res Rev       Date:  2000-07       Impact factor: 12.944

5.  Microwave-assisted decarboxylation of bicyclic 2-pyridone scaffolds and identification of Abeta-peptide aggregation inhibitors.

Authors:  Veronica Aberg; Fredrik Norman; Erik Chorell; Andreas Westermark; Anders Olofsson; A Elisabeth Sauer-Eriksson; Fredrik Almqvist
Journal:  Org Biomol Chem       Date:  2005-06-29       Impact factor: 3.876

6.  Discovery of Highly Potent 2-Sulfonyl-Pyrimidinyl Derivatives for Apoptosis Inhibition and Ischemia Treatment.

Authors:  Li Li; Xian Jiang; Shaoqiang Huang; Zhengxin Ying; Zhaolan Zhang; Chenjie Pan; Sisi Li; Xiaodong Wang; Zhiyuan Zhang
Journal:  ACS Med Chem Lett       Date:  2017-03-01       Impact factor: 4.345

7.  True symmetry or pseudosymmetry: 5-amino-1-(4-methylphenylsulfonyl)-4-pyrazolin-3-one and a comparison with its 1-phenylsulfonyl analogue.

Authors:  Galal H Elgemeie; Shahinaz H Sayed; Peter G Jones
Journal:  Acta Crystallogr C       Date:  2012-12-15       Impact factor: 1.172

8.  Synthesis and structure-activity relationships of 4-pyridones as potential antimalarials.

Authors:  Clive L Yeates; John F Batchelor; Edward C Capon; Neil J Cheesman; Mitch Fry; Alan T Hudson; Mary Pudney; Helen Trimming; James Woolven; José M Bueno; Jesús Chicharro; Esther Fernández; José M Fiandor; Domingo Gargallo-Viola; Federico Gómez de las Heras; Esperanza Herreros; María L León
Journal:  J Med Chem       Date:  2008-04-09       Impact factor: 7.446

9.  Crystal structure of 4-{[(cyano-imino)(methyl-sulfanyl)meth-yl]amino}-1,5-dimethyl-2-phenyl-2,3-di-hydro-1H-pyrazol-3-one.

Authors:  Galal H Elgemeie; Mamdouh Abouzeid; Peter G Jones
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2015-01-01

10.  Crystal structure of N'-[2-(benzo[d]thia-zol-2-yl)acet-yl]-4-methyl-benzene-sulfono-hydrazide.

Authors:  Rasha A Azzam; Galal H Elgemeie; Rasha E Elsayed; Peter G Jones
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2017-06-16
View more
  3 in total

1.  Derivatives of a new heterocyclic system - pyrano[3,4-c][1,2,4]triazolo[4,3-a]pyridines: synthesis, docking analysis and neurotropic activity.

Authors:  Ervand G Paronikyan; Anthi Petrou; Maria Fesatidou; Athina Geronikaki; Shushanik Sh Dashyan; Suren S Mamyan; Ruzanna G Paronikyan; Ivetta M Nazaryan; Hasmik H Hakopyan
Journal:  Medchemcomm       Date:  2019-06-19       Impact factor: 3.597

2.  Novel purine thioglycoside analogs: synthesis, nanoformulation and biological evaluation in in vitro human liver and breast cancer models.

Authors:  Mamdouh A Abu-Zaied; Samah A Loutfy; Ashraf E Hassan; Galal H Elgemeie
Journal:  Drug Des Devel Ther       Date:  2019-07-26       Impact factor: 4.319

3.  Efficient Synthesis and Docking Studies of Novel Benzothiazole-Based Pyrimidinesulfonamide Scaffolds as New Antiviral Agents and Hsp90α Inhibitors.

Authors:  Rasha A Azzam; Rokia R Osman; Galal H Elgemeie
Journal:  ACS Omega       Date:  2020-01-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.